-
公开(公告)号:EP2079678A2
公开(公告)日:2009-07-22
申请号:EP07866730.0
申请日:2007-10-15
IPC分类号: C07C217/16 , C07C229/18 , C07C229/24
CPC分类号: C07C271/28 , C07C229/18 , C07C229/24 , C07C235/46 , C07C235/54 , C07C311/16 , C07C311/20 , C07C2601/04 , C07C2601/14 , C07C2602/42 , C07D295/192 , C07D295/26 , C07D333/28
摘要: The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta(TR-Beta). Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them.
摘要翻译: 本发明涉及作为甲状腺受体配体的通式(I)的新化合物,优选甲状腺激素受体β(TR-β)的选择性。 此外,本发明涉及制备这些化合物的方法,它们的互变异构形式,涉及其合成的新中间体,其药学上可接受的盐,使用这些化合物的方法和含有它们的药物组合物。
-
公开(公告)号:EP3481809A1
公开(公告)日:2019-05-15
申请号:EP17751474.2
申请日:2017-07-13
IPC分类号: C07D263/56 , C07D413/04 , C07D413/12 , C07D263/32 , C07D271/06 , A61K31/4245 , A61K31/421 , A61K31/423 , A61K31/4439 , A61K31/497 , A61P29/00 , A61P37/00
-
公开(公告)号:EP2079678B1
公开(公告)日:2012-12-19
申请号:EP07866730.0
申请日:2007-10-15
IPC分类号: C07C235/46 , C07C235/54 , C07C271/28 , C07C311/16 , C07C311/20 , C07D333/28 , C07D295/192 , C07D295/26 , C07C229/18 , C07C229/24 , C07C217/16
CPC分类号: C07C271/28 , C07C229/18 , C07C229/24 , C07C235/46 , C07C235/54 , C07C311/16 , C07C311/20 , C07C2601/04 , C07C2601/14 , C07C2602/42 , C07D295/192 , C07D295/26 , C07D333/28
-
公开(公告)号:EP2346814A2
公开(公告)日:2011-07-27
申请号:EP09810886.3
申请日:2009-10-22
发明人: RAVAL, Saurin , RAVAL, Preeti
IPC分类号: C07C251/60 , C07C311/29 , C07C317/22 , C07D207/48 , C07D211/96 , A61K31/192
CPC分类号: C07C251/60 , C07C311/29 , C07C317/22 , C07C2601/14 , C07C2602/42 , C07D207/48 , C07D211/96
摘要: The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta (TR-Beta). Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, methods for using such compounds and pharmaceutical compositions containing them.
摘要翻译: 本发明涉及作为甲状腺受体配体的通式(I)的新化合物,优选甲状腺激素受体β(TR-β)的选择性。 此外,本发明涉及制备这些化合物的方法,它们的互变异构形式,涉及其合成的新中间体,其药学上可接受的盐,使用这些化合物的方法和含有它们的药物组合物。
-
-
-